Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity.

Ochaba J, Powers AF, Tremble KA, Greenlee S, Post NM, Matson JE, MacLeod AR, Guo S, Aghajan M.

Nucleic Acids Res. 2019 Oct 15. pii: gkz901. doi: 10.1093/nar/gkz901. [Epub ahead of print]

PMID:
31612951
2.

Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury.

Win S, Min RW, Chen CQ, Zhang J, Chen Y, Li M, Suzuki A, Abdelmalek MF, Wang Y, Aghajan M, Aung FW, Diehl AM, Davis RJ, Than TA, Kaplowitz N.

J Clin Invest. 2019 Sep 5. pii: 128289. doi: 10.1172/JCI128289. [Epub ahead of print]

3.

Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.

Aghajan M, Booten SL, Althage M, Hart CE, Ericsson A, Maxvall I, Ochaba J, Menschik-Lundin A, Hartleib J, Kuntz S, Gattis D, Ahlström C, Watt AT, Engelhardt JA, Monia BP, Magnone MC, Guo S.

JCI Insight. 2019 Jun 20;4(12). pii: 126124. doi: 10.1172/jci.insight.126124. eCollection 2019 Jun 20.

4.

Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations.

Huang L, Aghajan M, Quesenberry T, Low A, Murray SF, Monia BP, Guo S.

Nucleic Acid Ther. 2019 Aug;29(4):175-186. doi: 10.1089/nat.2019.0779. Epub 2019 May 9.

5.

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.

Cansby E, Nuñez-Durán E, Magnusson E, Amrutkar M, Booten SL, Kulkarni NM, Svensson LT, Borén J, Marschall HU, Aghajan M, Mahlapuu M.

Cell Mol Gastroenterol Hepatol. 2019;7(3):597-618. doi: 10.1016/j.jcmgh.2018.12.004. Epub 2018 Dec 19.

6.

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice.

Nuñez-Durán E, Aghajan M, Amrutkar M, Sütt S, Cansby E, Booten SL, Watt A, Ståhlman M, Stefan N, Häring HU, Staiger H, Borén J, Marschall HU, Mahlapuu M.

Hepatol Commun. 2017 Nov 20;2(1):69-83. doi: 10.1002/hep4.1128. eCollection 2018 Jan.

7.

Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.

Aghajan M, Guo S, Monia BP.

Methods Mol Biol. 2017;1639:127-138. doi: 10.1007/978-1-4939-7163-3_12.

PMID:
28752452
8.

The role of MAP2 kinases and p38 kinase in acute murine liver injury models.

Zhang J, Min RWM, Le K, Zhou S, Aghajan M, Than TA, Win S, Kaplowitz N.

Cell Death Dis. 2017 Jun 29;8(6):e2903. doi: 10.1038/cddis.2017.295.

9.

Protective role of p53 in acetaminophen hepatotoxicity.

Huo Y, Yin S, Yan M, Win S, Aung Than T, Aghajan M, Hu H, Kaplowitz N.

Free Radic Biol Med. 2017 May;106:111-117. doi: 10.1016/j.freeradbiomed.2017.02.028. Epub 2017 Feb 11.

10.

Knockdown of RIPK1 Markedly Exacerbates Murine Immune-Mediated Liver Injury through Massive Apoptosis of Hepatocytes, Independent of Necroptosis and Inhibition of NF-κB.

Suda J, Dara L, Yang L, Aghajan M, Song Y, Kaplowitz N, Liu ZX.

J Immunol. 2016 Oct 15;197(8):3120-3129. Epub 2016 Sep 7.

11.

Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.

Prakash TP, Yu J, Migawa MT, Kinberger GA, Wan WB, Østergaard ME, Carty RL, Vasquez G, Low A, Chappell A, Schmidt K, Aghajan M, Crosby J, Murray HM, Booten SL, Hsiao J, Soriano A, Machemer T, Cauntay P, Burel SA, Murray SF, Gaus H, Graham MJ, Swayze EE, Seth PP.

J Med Chem. 2016 Mar 24;59(6):2718-33. doi: 10.1021/acs.jmedchem.5b01948. Epub 2016 Mar 9.

PMID:
26914862
12.

c-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src.

Win S, Than TA, Min RW, Aghajan M, Kaplowitz N.

Hepatology. 2016 Jun;63(6):1987-2003. doi: 10.1002/hep.28486. Epub 2016 Mar 15.

13.

Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S.

Haematologica. 2016 Jan;101(1):e8-e11. doi: 10.3324/haematol.2015.133348. Epub 2015 Sep 24. No abstract available.

14.

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP.

Nucleic Acids Res. 2014 Jul;42(13):8796-807. doi: 10.1093/nar/gku531. Epub 2014 Jul 3.

15.

Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.

Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN, Karin M.

Cell Metab. 2014 Jul 1;20(1):133-44. doi: 10.1016/j.cmet.2014.05.001. Epub 2014 Jun 5.

16.

Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

Guo S, Booten SL, Aghajan M, Hung G, Zhao C, Blomenkamp K, Gattis D, Watt A, Freier SM, Teckman JH, McCaleb ML, Monia BP.

J Clin Invest. 2014 Jan;124(1):251-61. doi: 10.1172/JCI67968. Epub 2013 Dec 20.

17.

Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S.

J Clin Invest. 2013 Apr;123(4):1531-41. doi: 10.1172/JCI66969. Epub 2013 Mar 25.

18.

Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3.

Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park HW, Bandyopadhyay G, Li N, Aghajan M, Jang I, Wolfe AM, Perkins GA, Ellisman MH, Bier E, Scadeng M, Foretz M, Viollet B, Olefsky J, Karin M.

Cell Metab. 2012 Sep 5;16(3):311-21. doi: 10.1016/j.cmet.2012.08.004.

19.

Obesity, autophagy and the pathogenesis of liver and pancreatic cancers.

Aghajan M, Li N, Karin M.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:10-4. doi: 10.1111/j.1440-1746.2011.07008.x. Review.

20.

Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase.

Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, Del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J.

Nat Biotechnol. 2010 Jul;28(7):738-42. doi: 10.1038/nbt.1645. Epub 2010 Jun 27.

21.

Target identification using drug affinity responsive target stability (DARTS).

Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, Wang J, Wu RP, Gomez F, Loo JA, Wohlschlegel JA, Vondriska TM, Pelletier J, Herschman HR, Clardy J, Clarke CF, Huang J.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21984-9. doi: 10.1073/pnas.0910040106. Epub 2009 Dec 7.

22.

Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1).

Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, Bazan JF, Fairbrother WJ, Deshayes K, Vucic D.

Biochem J. 2009 Jan 1;417(1):149-60. doi: 10.1042/BJ20081885.

PMID:
18939944
23.

A multi-enzyme model for Pyrosequencing.

Agah A, Aghajan M, Mashayekhi F, Amini S, Davis RW, Plummer JD, Ronaghi M, Griffin PB.

Nucleic Acids Res. 2004 Dec 2;32(21):e166.

Supplemental Content

Loading ...
Support Center